trending Market Intelligence /marketintelligence/en/news-insights/trending/FzSH_PKWGtQvINtQfJydJg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Health Sciences becomes Immunovant at closure of $395M acquisition

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Health Sciences becomes Immunovant at closure of $395M acquisition

Immunovant Inc., formerly called Health Sciences Acquisitions Corp., has closed its acquisition of Immunovant Sciences in a deal valued at about $395 million.

The merger, announced in October, makes the original Immunovant Sciences a wholly owned subsidiary of the former Health Sciences, the combined company adopting the name Immunovant.

Shareholders of Health Sciences approved the deal at a Dec. 16 meeting, and the new company will trade under the symbol IMVT on Nasdaq.

Immunovant specializes in autoimmune diseases and is developing the drug IMVT-1401 with its partner, HanAll Biopharma.